Extraordinarily Elevated Ca19-9 in Benign Conditions: A Case Report and Review of the Literature

Akdoğan, Meral; Şaşmaz, Nurgül; Kayhan, Burçak; Biyikoglu, Ibrahim; Dışıbeyaz, Selçuk; Şahın, Burhan

doi:10.1177/030089160108700513

Cited by 59 publications

(41 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, CA 19-9 may be increased in other malignancies such as ovarian cancer, colon cancer, and gastric cancer (16). In addition, CA 19-9 increases have been reported in various benign conditions such as Hashimoto's thyroiditis (16), benign biliopancreatic diseases (17), and several lung diseases (6)(7)(8)(9). In the present study, 11 (8.5%) out of 130 participants with increased CA 19-9 had malignancy; only five of which had pancreatic cancer.…”

Section: Discussionmentioning

confidence: 99%

Increased CA 19-9 level in patients without malignant disease

Kim

Lee

Kim

et al. 2009

Clinical Chemistry and Laboratory Medicine

View full text Add to dashboard Cite

Background: The measurement of carbohydrate antigen 19-9 (CA 19-9) is recommended for the diagnosis and follow-up of pancreatic cancer. However, increased CA 19-9 has also been reported in patients with various benign diseases of the lung. We aimed to elucidate the pulmonary radiographic abnormalities and laboratory results associated with increased concentrations of CA 19-9. Methods: This study was performed using a case-controlled design. Cases included all participants in a cancer screening program who had an increased CA 19-9 concentration ()37 U/mL), but without a diagnosis of malignancy. Age-and sex-matched participants with normal CA 19-9 levels were enrolled as controls. Laboratory results and radiographic features were compared. Results: In total, 119 participants with increased CA 19-9 concentrations and 476 controls were included. A higher erythrocyte sedimentation rate (ESR) wadjusted odd ratio (aOR), 1.03; 95% confidence interval (CI), 1.01-1.05x, higher hemoglobin A 1c (HbA 1c

show abstract

Section: Discussionmentioning

confidence: 99%

Increased CA 19-9 level in patients without malignant disease

Kim

Lee

Kim

et al. 2009

Clinical Chemistry and Laboratory Medicine

View full text Add to dashboard Cite

show abstract

“…Unfortunately tumor markers that are currently utilized for the detection of pancreatic cancer in clinical practice lack the sensitivity and specificity needed to detect potentially curable lesions. For example, serum CA-19-9 is considered the best test for pancreatic cancer (3); however, CA-19-9 can also be elevated in a myriad of non-neoplastic conditions such as acute and chronic pancreatitis, hepatitis, and biliary obstruction, greatly diminishing its specificity (4). In addition, patients with certain blood group antigen types do not express the CA-19-9 antigen.…”

mentioning

confidence: 99%

Biomarker Discovery from Pancreatic Cancer Secretome Using a Differential Proteomic Approach

Grønborg

Kristiansen

Iwahori

et al. 2006

Molecular & Cellular Proteomics

433

336

View full text Add to dashboard Cite

Quantitative proteomics can be used as a screening tool for identification of differentially expressed proteins as potential biomarkers for cancers. Candidate biomarkers from such studies can subsequently be tested using other techniques for use in early detection of cancers. Here we demonstrate the use of stable isotope labeling with amino acids in cell culture (SILAC) method to compare the secreted proteins (secretome) from pancreatic cancer-derived cells with that from non-neoplastic pancreatic ductal cells. We identified 145 differentially secreted proteins (>1.5-fold change), several of which were previously reported as either up-regulated (e.g. cathepsin D, macrophage colony stimulation factor, and fibronectin receptor) or down-regulated (e.g. profilin 1 and IGFBP-7) proteins in pancreatic cancer, confirming the validity of our approach. In addition, we identified several proteins that have not been correlated previously with pancreatic cancer including perlecan (HSPG2), CD9 antigen, fibronectin receptor (integrin ␤1), and a novel cytokine designated as predicted osteoblast protein (FAM3C). The differential expression of a subset of these novel proteins was validated by Western blot analysis. In addition, overexpression of several proteins not described previously to be elevated in human pancreatic cancer (CD9, perlecan, SDF4, apoE, and fibronectin receptor) was confirmed by immunohistochemical labeling using pancreatic cancer tissue microarrays suggesting that these could be further pursued as potential biomarkers. Lastly the protein expression data from SILAC were compared with mRNA expression data obtained using

show abstract

“…There are a few reports related to extraordinarily high levels of CA 19-9 and cholangitis (16,(18)(19)(20)(21)(22). Although the real reason for the CA 19-9 elevation in cholangitis is not clear, several mechanisms as mentioned above have been postulated.…”

Section: Patients With Choledocholithiasismentioning

confidence: 99%

“…In addition to these reports, elevations of CA 19-9 to extraordinarily high levels without pancreatic or other gastrointestinal malignancies have also been reported in patients, particularly with choledocholithiasis and cholangitis (16,(18)(19)(20)(21)(22). In light of the foregoing, it is impossible for the clinician not to consider malignancy when he is dealing with an older patient with obstructive jaundice and extremely elevated CA 19-9 levels.…”

Section: Introductionmentioning

confidence: 98%